Chitosan-based hydrogels for developing a small-diameter vascular graft:
 in vitro
 and
 in vivo
 evaluation

Aussel, Audrey; Thebaud, Noëlie; Bérard, Xavier; Brizzi, Vincenzo; Delmond, Samantha; Bareille, Reine; Siadous, Robin; James, Chloé; Ripoche, Jean; Durand, M.; Montembault, Alexandra; Burdin, Béatrice; Letourneur, Didier; L’Heureux, Nicolas; David, Laurent; Bordenave, Laurence

doi:10.1088/1748-605x/aa78d0

Cited by 40 publications

(25 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…S1). Exclusion of duplicates and then systematic screening of title and abstract using the Covidence platform revealed 321 studies, which was finally limited by thorough text reading to 68 studies based on inclusion criteria . These studies represented a total of 873 grafts: 258 occluded and 615 patent grafts at the end of the evaluation period.…”

Section: Resultsmentioning

confidence: 99%

Concise Review: Patency of Small-Diameter Tissue-Engineered Vascular Grafts: A Meta-Analysis of Preclinical Trials

Skovrind

Harvald

Belling

et al. 2019

Stem Cells Translational Medicine

View full text Add to dashboard Cite

Several patient groups undergoing small‐diameter (<6 mm) vessel bypass surgery have limited autologous vessels for use as grafts. Tissue‐engineered vascular grafts (TEVG) have been suggested as an alternative, but the ideal TEVG remains to be generated, and a systematic overview and meta‐analysis of clinically relevant studies is lacking. We systematically searched PubMed and Embase databases for (pre)clinical trials and identified three clinical and 68 preclinical trials ([>rabbit]; 873 TEVGs) meeting the inclusion criteria. Preclinical trials represented low to medium risk of bias, and binary logistic regression revealed that patency was significantly affected by recellularization, TEVG length, TEVG diameter, surface modification, and preconditioning. In contrast, scaffold types were less important. The patency was 63.5%, 89%, and 100% for TEVGs with a median diameter of 3 mm, 4 mm, and 5 mm, respectively. In the group of recellularized TEVGs, patency was not improved by using smooth muscle cells in addition to endothelial cells nor affected by the endothelial origin, but seems to benefit from a long‐term (46–240 hours) recellularization time. Finally, data showed that median TEVG length (5 cm) and median follow‐up (56 days) used in preclinical settings are relatively inadequate for direct clinical translation. In conclusion, our data imply that future studies should consider a TEVG design that at least includes endothelial recellularization and bioreactor preconditioning, and we suggest that more standard guidelines for testing and reporting TEVGs in large animals should be considered to enable interstudy comparisons and favor a robust and reproducible outcome as well as clinical translation.

show abstract

Section: Resultsmentioning

confidence: 99%

Concise Review: Patency of Small-Diameter Tissue-Engineered Vascular Grafts: A Meta-Analysis of Preclinical Trials

Skovrind

Harvald

Belling

et al. 2019

Stem Cells Translational Medicine

View full text Add to dashboard Cite

show abstract

“…The results showed that the prepared hydrogels were hemocompatible and did not induce any significant hemolysis in comparison with the negative control groups ( p < .3). The hemocompatibility of chitosan‐based hydrogels has been reported in various studies 46–48 . As shown in Figure 4, the incorporation of tEDTA slightly increased the hemolysis percent, while adding AV reduced the hemolysis.…”

Section: Resultsmentioning

confidence: 71%

“…The hemocompatibility of chitosan-based hydrogels has been reported in various studies. [46][47][48] As shown in Figure 4, the incorporation of tEDTA slightly increased the hemolysis percent, while adding AV reduced the hemolysis. Moreover, the difference between the samples (other than positive control) was not statistically significant (p < .4).…”

Section: Hemocompatibility Resultsmentioning

confidence: 79%

Chitosan hydrogel loaded with Aloe vera gel and tetrasodium ethylenediaminetetraacetic acid (EDTA) as the wound healing material: in vitro and in vivo study

Salehi

Zamiri

Samadian

et al. 2020

J of Applied Polymer Sci

View full text Add to dashboard Cite

The main aim of the current study was to develop a chitosan hydrogel containing Aloe vera gel and Ethylenediaminetetraacetic acid (EDTA) as the wound healing materials. Chitosan with the concentration of (2% w/v) was prepared in AA (0.5%, v/v) and Tetrasodium EDTA (0.01% w/w) and AV (0.5% v/v) were added to the prepared polymer solution. As prepared solution was cross‐linked by β‐GP with the weight ratio of 1/6 w/w (1 chitosan and 6 β‐GP). The characterization of the hydrogels showed that the hydrogels have porous structures and interconnected pores with the pores size range from 41.5 ± 14 to 48.3 ± 11 μm. The swelling and weight loss measurements of the hydrogels showed that the hydrogels could swell up to 240% of their initial weight during 8 h and loss 79.7 ± 3.5% of the initial weight during 14 days. The antibacterial studies depicted that the prepared Cs/tEDTA/AV hydrogel inhibited the growth of Staphylococcus aureus (the minimum inhibition concentration, MIC of 73 ± 4.8) and Pseudomonas aeruginosa (the MIC of 40 ± 7.9). Moreover, the prepared hydrogels were hemocompatible (Cs/tEDTA/AV: OD of 0.24 ± 0.30) and biocompatible (Cs/tEDTA/AV: OD of 0.38 ± 0.01). At the final stage, the wound healing assessments in the animal model revealed that the application of the prepared hydrogels effectively enhanced the wound healing process. In conclusion, the results confirmed the efficacy of the prepared hydrogels as the wound healing materials.

show abstract

“…Results from in vivo studies in small and large animals (rat and sheep) and in vitro studies of chitosanbased hydrogels indicated that the hydrogel exhibited good hemocompatibility properties in vivo and promising in vitro biocompatibility. 85 The electrical properties of implanted grafts are significant challenges for the regeneration of infarcted heart tissue. Distribution of AuNPs throughout chitosan is one way to enhance electrical coupling between adjacent cells within chitosan scaffolds.…”

Section: Chitosanmentioning

confidence: 99%

Biodegradable Nanopolymers in Cardiac Tissue Engineering: From Concept Towards Nanomedicine

Nasr¹,

Rabiee²,

Hajebi³

et al. 2020

IJN

103

View full text Add to dashboard Cite

Cardiovascular diseases are the number one cause of heart failure and death in the world, and the transplantation of the heart is an effective and viable choice for treatment despite presenting many disadvantages (most notably, transplant heart availability). To overcome this problem, cardiac tissue engineering is considered a promising approach by using implantable artificial blood vessels, injectable gels, and cardiac patches (to name a few) made from biodegradable polymers. Biodegradable polymers are classified into two main categories: natural and synthetic polymers. Natural biodegradable polymers have some distinct advantages such as biodegradability, abundant availability, and renewability but have some significant drawbacks such as rapid degradation, insufficient electrical conductivity, immunological reaction, and poor mechanical properties for cardiac tissue engineering. Synthetic biodegradable polymers have some advantages such as strong mechanical properties, controlled structure, great processing flexibility, and usually no immunological concerns; however, they have some drawbacks such as a lack of cell attachment and possible low biocompatibility. Some applications have combined the best of both and exciting new natural/ synthetic composites have been utilized. Recently, the use of nanostructured polymers and polymer nanocomposites has revolutionized the field of cardiac tissue engineering due to their enhanced mechanical, electrical, and surface properties promoting tissue growth. In this review, recent research on the use of biodegradable natural/synthetic nanocomposite polymers in cardiac tissue engineering is presented with forward looking thoughts provided for what is needed for the field to mature.

show abstract

Chitosan-based hydrogels for developing a small-diameter vascular graft: in vitro and in vivo evaluation

Abstract: Chitosan-based hydrogels displayed promising in vitro biocompatibility and hemocompatibility properties as well as in vivo short-term performance.

Cited by 40 publications

References 42 publications

Concise Review: Patency of Small-Diameter Tissue-Engineered Vascular Grafts: A Meta-Analysis of Preclinical Trials

Concise Review: Patency of Small-Diameter Tissue-Engineered Vascular Grafts: A Meta-Analysis of Preclinical Trials

Chitosan hydrogel loaded with Aloe vera gel and tetrasodium ethylenediaminetetraacetic acid (EDTA) as the wound healing material: in vitro and in vivo study

<p>Biodegradable Nanopolymers in Cardiac Tissue Engineering: From Concept Towards Nanomedicine</p>

Contact Info

Product

Resources

About